Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus abiraterone and prednisone/prednisolone versus placebo plus abiraterone and prednisone/prednisolone in previously untreated metastatic castration-resistant prostate cancer
MOH_2017-06-28_000521Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipatasertib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Roche. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2017-06-28_000521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-28_000521.